ELAN — Elanco Animal Health Incorporated stock price, charts and financials

QT80Elanco Animal Health Incorporated

Elanco Animal Health Incorporated (NYSE: ELAN) is a Healthcare company in the Drug Manufacturers - Specialty & Generic industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
25.72
-0.65-2.46%
ELANQT80Elanco Animal Health Incorporated·NYSE
25.72-2.46%
TA
Loading chart...
Screen all →
Snapshot
Index-P/E-EPS (ttm)-0.49Insider Own1.13%Shs Outstand499.45MPerf Week5.86%
Market Cap13.18BForward P/E21.99EPS next Y1.20Insider Trans0.17%Shs Float494.82MPerf Month9.46%
Enterprise Value16.74BPEG0.34EPS next Q-Inst Own-Short Float7.24%Perf Quarter17.88%
Income-242.52MP/S2.69EPS this Y317.43%Inst Trans-Short Ratio6.23Perf Half Y8.97%
Sales4.89BP/B2.02EPS next Y12.54%ROA-1.83%Short Interest35.82MPerf YTD16.53%
Book/sh-P/C22.76EPS next 5Y9.56%ROE-3.64%52W High27.04 -4.87%Perf Year86.76%
Cash/sh-P/FCF41.84EPS past 3/5Y-ROIC3.77%52W Low13.06 96.94%Perf 3Y116.50%
Dividend Est.-EV/EBITDA21.92Sales past 3/5Y2.25% 7.57%Gross Margin49.44%Volatility2.94% 3.33%Perf 5Y-27.75%
Dividend TTM-EV/Sales3.42EPS Y/Y TTM-172.06%Oper. Margin8.95%ATR (14)0.88Perf 10Y-
Dividend Ex-Date-Quick Ratio1.12Sales Y/Y TTM10.23%Profit Margin-4.95%RSI (14)63.11Recom2.38
Dividend Gr. 3/5Y-Current Ratio2.16EPS Q/Q8.11%SMA203.88%Beta1.66Target Price28.33
Payout0.00%Debt/Eq0.61Sales Q/Q14.92%SMA508.08%Rel Volume0.88Prev Close26.37
Employees9,900LT Debt/Eq0.60EarningsAug 05SMA20012.43%Avg Volume5.89MPrice25.72
IPO DateSep 20, 2018Option/ShortYes / YesEPS/Sales Surpr.15.75% 7.35%Net Debt/EBITDA4.66Volume5,193,836Change-2.46%
Analyst Ratings
DateActionAnalystRatingTarget
Jul-22-26ReiteratedMorgan StanleyEqual Weight$23$26
May-15-26ReiteratedMorgan StanleyEqual Weight$24$23
Feb-25-26ReiteratedKeybancOverweight$27$29
Feb-24-26ReiteratedLeerink PartnersOutperform$18$30
Jan-29-26ReiteratedUBSBuy$27$30
Jan-22-26UpgradePiper SandlerNeutralOverweight$12$30
Dec-18-25ReiteratedMorgan StanleyEqual Weight$37$22
Dec-08-25InitiatedBarclaysOverweight$22$30
Nov-20-25InitiatedKeyBancOverweight$27
Nov-19-25ReiteratedArgus ResearchBuy$25
Latest News
Jul-31-26
Jul-29-26
Jul-27-26
Jul-23-26
Jul-22-26
Jul-18-26
Jul-16-26
Jul-15-26
Jul-08-26
Jun-30-26
Jun-25-26
Jun-24-26
Jun-22-26
Company

Elanco Animal Health, a firm dedicated to animal well-being, creates, produces, and commercializes a diverse array of solutions for both companion animals and livestock. For household pets, the company provides preventative health solutions, including parasiticides and vaccinations, designed to guard against common ailments like worms, fleas, and ticks, with notable brands such as Seresto, Advantage, Advantix, and Advocate. Additionally, Elanco supplies therapeutic treatments for canine and feline conditions including pain, osteoarthritis, ear infections, cardiovascular issues, and dermatological problems, marketed under labels like Galliprant and Claro. Its portfolio for agricultural animals encompasses vaccines, antibiotics, parasiticides, and other essential products for poultry and aquaculture farming. This segment also features nutritional supplements such as enzymes, probiotics, and prebiotics to support animal health and growth. Furthermore, the company offers a comprehensive suite of products for ruminant and swine operations, comprising vaccines, antibiotics, implants, and parasiticides, often recognized by brands like Rumensin and Baytril. Elanco distributes its offerings through various channels, including independent distributors, veterinary clinics, and a broad spectrum of farm animal producers, from cattle and dairy farms to pig, poultry, and aquaculture enterprises. Established in 1954, Elanco Animal Health Incorporated maintains its corporate headquarters in Greenfield, Indiana.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue4,8934,7154,4394,4174,4114,7643,2733,0713,067
Cost of Goods Sold Incl. D&A2,4742,6652,5302,4792,4412,6882,0271,6711,771
Gross Profit2,4192,0501,9091,9381,9702,0761,2471,4001,296
Selling, General and Administrative Excl. Other1,4701,4301,3141,2851,2651,403997760735
Research and Development371368344327321369327270247
Other Operating Expense
14000000000
Operating Income438252251326384304-77370314
Interest Expense2702203392772562641567930
Unusual Expense
Non-Operating Income (Expense)-365-256576-1,244-200-611-439-213-170
Net Income Before Taxes-197-224488-1,195-72-571-67278114
Income Taxes458150366-88-1121028
Consolidated Net Income-242-232338-1,231-78-483-5606887
Net Income From Continuing Operations-242-232338-1,231-78-483-5606887
Net Income-242-232338-1,231-78-483-5606887
EPS (Recurring)-0.50-0.470.68-2.50-0.15-0.97-1.270.180.28
EPS (Basic, Before Extraordinaries)-0.50-0.470.68-2.50-0.15-0.97-1.270.180.28
EPS (Diluted)-0.49-0.470.68-2.50-0.15-0.97-1.270.180.28
EBITDA7646761,489-2248664091472440
Other After Tax Adjustments
Stock Option Compensation Expense
Price To Earnings Ratio17.81163.61112.61
Price To Sales Ratio2.622.381.351.661.352.904.133.543.23
Gross Margin49.4443.4843.0143.8844.6643.5838.1045.5942.26
Operating Margin8.955.345.657.388.716.38-2.3512.0510.24
Net Margin-4.95-4.927.61-27.87-1.77-10.14-17.112.212.84
Shares Outstanding498496494492488487441369314
Market Capitalization12,80911,2245,9827,3315,96313,82113,52510,8679,900
Operating Lease Expense
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$28.97$24.36$19.75$15.14$10.53 Close Price0.00K234.48K468.95K703.43K937.91KUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Modi Rajeev A.SEE REMARKSMay 15 '26Buy20.354,91199,939160,812May 19
Simmons Jeffrey NPRESIDENT, CEO AND DIRECTORMay 15 '26Buy20.094,97199,843171,971May 19
Kurzius Lawrence ErikDirectorDec 12 '25Buy21.3010,000213,000131,773Dec 16
Modi Rajeev A.SEE REMARKSDec 11 '25Buy21.334,50095,985123,082Dec 15
VanHimbergen Robert MEVP and CFODec 11 '25Buy21.646,950150,426124,233Dec 15
Simmons Jeffrey NPRESIDENT, CEO AND DIRECTORDec 11 '25Buy21.7522,000478,496167,000Dec 15
Kurzius Lawrence ErikDirectorMar 11 '25Buy10.2010,000102,000111,459Mar 11
Kurzius Lawrence ErikDirectorMar 07 '25Buy10.9010,000109,000101,459Mar 11
HOOVER R DAVIDDirectorMar 05 '25Buy10.9025,000272,558210,000Mar 07
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.